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ABSTRACT
Ependymoma is a primary solid tumor of the central nervous system. Supratentorial
ependymoma (ST-EPN), a subtype of ependymomas, is driven by an oncogenic fusion between
the ZFTA and RELA genes in 70% of cases. We introduced this fusion into neural progenitor
cells of mice embryos via in utero electroporation of a non-viral binary piggyBac transposon
system containing ZFTA-RELA. From preliminary data in the LoTurco lab, inducing the
expression of ZFTA-RELA into different neural progenitor cells produces tumors of varying
lethality and cellular composition. To define the cellular composition and subclonal diversity of
ST-EPN tumors, we used single cell RNA-sequencing to derive a transcriptomic profile of the
heterogeneous cell types composing ST-EPN mouse tumors. Among the 20,000 cells sequenced,
approximately two-thirds of the cells did not express the oncogene. These cells represent various
types of immune cells, such as B-lymphocytes, T-cells, and macrophages; stromal cells, and
different neural cell types (i.e. oligodendrocytes). Although ZFTA-RELA has been shown to
activate NF-κB effector genes, there was not a ubiquitous upregulation of such genes across the
cells enriched for ZFTA-RELA expression. Subclustering these tumorigenic cells revealed
distinct subpopulations characterized by upregulation of non-NFκB pathways involved in cell
proliferation, extracellular environment reorganization, and immune activation. We identified a
list of specific markers for these cellular conditions to better characterize the processes
underlying ST-EPN aggressiveness and immunological responses.
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INTRODUCTION
Brain tumors are the leading cause of death among all childhood cancers[10].
Ependymoma is the third most common type of pediatric brain tumor. It forms along the
ependymal walls of cerebral ventricles and central regions of the spinal cord[15,17]. Based upon its
developmental compartment in the central nervous system (CNS), ependymoma is subclassified
as posterior fossa (PF), supratentorial (ST), and spinal (SP)[6,15,17]. Regardless of location,
standard treatment involves extensive surgical resection followed by local radiation therapy,
which may incur complications in the developing brain[6,11,14,15]. Currently, there are no reports
of chemotherapeutic agents with proven efficacy against these tumors[6,15]. Insight into the
biological processes generating these tumors may inform better therapeutic strategies.
Significant efforts have been made to define the molecular basis of ependymoma
subtypes. Recently, molecular analysis of supratentorial ependymoma (ST-EPN), which
constitutes 30% of ependymomas, has identified an oncogenic fusion between the ZFTA and
RELA genes in 70% of ST-EPNs[10]. ST-EPNs with the ZFTA-RELA fusion often display
aggressive clinical behavior and are associated with poor outcomes[6,14,15]. The ZFTA-RELA
fusion may be an actionable therapeutic target since it appears specific for ST-EPN. Investigating
the cell types affected by this mutation may help direct a novel targeted therapy approach for STEPN.
The ZFTA-RELA fusion is caused by dramatic fragmental rearrangements confined in a
genomic region, known as chromothripsis[14]. Experimental evidence showed that the ZFTARELA fusion can initiate the formation of ST-EPN, and activates the NF-κB cellular pathway
involved in DNA transcription, cell survival, and inflammation response[6,13,14]. RELA encodes
the protein p65, a major component of the NF-κB pathway[6,13,14]. The presence of four zinc-
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finger domains in the protein encoded by ZFTA mediates its spontaneous translocation to the
nucleus, where it binds to designated motifs across the genome[1,9]. Recent studies show that
ZFTA is necessary for the ZFTA-RELA fusion protein to localize to the nucleus and modulate
chromatin at genic regions associated with ST-EPN, allowing the RELA transactivation domain
(TAD) to induce their transcription[1,9].
Single-cell RNA sequencing (scRNA-seq) is a technique that utilizes optimized NextGeneration Sequencing methods to derive a gene expression profile of single cells (i.e.
transcriptome) [12,16,22,24]. It can be used to identify different cell types present within the tumor
microenvironment, including stromal (non-tumor), immune, and proliferating tumor cells; and
their roles in tumorigenesis[16,22]. Applying this approach has detailed cell subpopulations
involved in the pathogenesis of many diseases, including cancers such as glioblastoma and
melanoma as well as neurological diseases such as Alzheimer’s Disease and Autism Spectrum
Disorder[12,16,22,24]. Researchers found that some transcriptionally diverse cell populations are
involved in disease initiation while others are implicated in disease progression[12,16,22,24]. In the
studies of glioblastoma and melanoma, functional profiling of the different cell types revealed
varying cell compositions across tumor subclones, suggestive of their differential impact on
tumor development[16,22].
In this study, we attempt to delineate the transcriptional program underlying
transformation by utilizing scRNA-seq to create a transcriptomic profile of ST-EPN. This
scRNA-seq dataset can be used to characterize the composition of cells across different ST-EPN
tumors as well as individual subclones of the same tumor, with the idea that variations in the cell
type expressing the ZFTA-RELA fusion may differentially alter biological processes contributing
to tumor malignancy.
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METHODS
Preparation of Plasmids
The human sequence of the ZFTA-RELA fusion was obtained from [14] and The Jackson
Laboratory for Genomic Medicine (Farmington, CT). An additional sequence for an HA tag was
added to the 3’ end of the fusion. A system of donor and helper piggyBac plasmids was used to
induce transgenesis of ZFTA-RELA in mice. For generation of the pPBCAG-ZFTA-RELA-HA
donor plasmid, DNA was prepared by Eurofins Genomics (Louisville, KY), PCR amplified, and
inserted into EcoRI/NotI sites of the piggyBac transposon donor plasmid pPBCAG-eGFP[3,4].
The helper plasmid pCAG-PBase was prepared as in [3, 4] and injected along with donor
plasmids pPBCAG-ZFTA-RELA-HA and pPBCAG-eGFP.
Animals
Pregnant female CD1 mice were obtained at embryonic day 13.5 -15.5 from Charles River
Laboratories, Inc. (Wilmington, MA), and housed in the Torrey Life Sciences vivarium. Mice
were kept in isolated cages with ad libitum access to standard lab chow, water, and enrichment
pieces. Gestation stages of the mice were determined via palpation before and during surgery.
Both male and female embryos were used in the experiment. All procedures were approved by
the University of Connecticut IACUC.
In-utero electroporation
Surgeries were performed at embryonic day 14 or 15 (E14 or E15), which was confirmed during
surgery. All plasmids were used at a final concentration of 1.0 μg/μL in sterile 1x phosphatebuffered saline (PBS) solution. In addition to donor and helper plasmids, 2 μL of 2 mg/mL Fast
Green (Sigma) dye was included in the mix to track the location of the injection. Mice were
anesthetized with isoflurane before their uterine horns were exposed. One lateral ventricle of
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each embryo was injected with 1-2 μL of the plasmid mix via pulses of air pressure through a
pulled glass microelectrode (Drummond Scientific) inserted through the embryonic membrane
and lateral ventricle. Application of pressure was made through a Picospritzer II (General
Valve). Voltages of 65-75 V by a BTX 8300 pulse generator (BTX Harvard Apparatus) and BTX
tweezertrodes were then applied to electroporate individual embryos. Pregnant mothers were
then sutured and returned to the animal colony with supervision and medication in adherence
with a two-day post-operative management protocol. Pups were born between E18-E21 gestation
age.
Tumor Cell Dissociation
At postnatal day 35, CD1 mice displaying evidence of tumor growth were harvested. From one
mice displaying pronounced hydrocephaly, a tumor was microdissected from the brain in Hank’s
Balanced Salt Solution (HBSS) solution with Ca2+/Mg2+ ions (Biological Industries Cat #: 02016-1A). Dissected tumor masses were transferred to fresh HBSS solution before being minced
into <1mm size chunks. In 2 mL microcentrifuge tubes, 1mL of an enzyme mix consisting of
50µg/mL 10x Dispase II (0.5 µg/mg stock) Sigma Cat#: D4693, 5mg/mL DNAse (1000 µg/mL
stock) Sigma Cat#: AMP-D1, and 50µg/mL 10X Collagenase Type IV (0.5% in HBSS,
50mg/10mL HBSS) Old Gibco Stock Cat#: 17104-019 (285u/mg), and DMEM 10% FBS was
prepared. All final concentrations were obtained through dilution in HBSS solution. After
mincing, two separate 30-50 mg samples of tumor tissue were transferred to the 1mL enzyme
cocktails, and set on a shaker to incubate at 37C for 2-3 hours in a water bath. The resultant
mixes were spun for two minutes at 2000g on a table top centrifuge, and the pellet cells were
resuspended in 500uL fresh HBSS. This process was repeated once more. A trypan blue stain
was applied to identify dead cells. Total cell numbers were counted using a chip cytometer. The
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ratio of alive:dead cells was calculated, along with the concentration of live cells (cells/uL). Cells
were concentrated to 1000 cells/uL in HBSS before being sent for single-cell RNA sequencing.
Single-Cell RNA Sequencing
Single nuclei were processed using the microfluidics-based 10X Chromium Single Cell 3’
Reagent Kits v3 (10X Genomics, PN-1000092, Pleasanton, CA). One sample of 20638 cells and
another of 20085 cells were separately added to their own chip channels and partitioned into Gel
Beads-in-emulsion (GEMs) on the Chromium Controller. Nuclei were lysed and barcoded with
RNA. Single-nuclei gel emulsions were broken to allow for library preparation, which included
the following steps: cDNA amplification, fragmentation, ligation of sample indexes, and addition
of Illumina P5/P7 adapters. The Cell Ranger pipeline (10X Genomics Cell Ranger 3.0.0) was
used to filter, align, and map raw library reads for analysis. The ZFTA-RELA sequence was
added to reference genome GRCm38 for aligning and mapping the reads.
Data Filtering and Integration
Filtered read counts were analyzed using the Seurat v3 [19] analysis pipeline on R Studio® [18].
Reads from the two separate runs were first individually normalized, scaled, and plotted based on
the t-distributed stochastic neighbor embedding[10] algorithm, which showed no significant batch
effects between the runs. Data from the separate samples was then integrated together using an
integration anchors method[19]. Following parameters set by the Seurat v3 Guided Clustering
Tutorial[18], cells with a high percentage of mitochondrial transcripts (>20%), high read counts
(>25000), and high gene feature counts (>6000) were filtered out to eliminate cell doublets and
low-confidence cells. A total of 23217 cells were further analyzed.
Clustering Cells Based on Differential Gene Expression
Cells were clustered according to the Seurat v3 Guided Clustering Tutorial[19]. Briefly, principal
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components analysis (PCA) was performed using the 2000 most variable expressed features
across all of the cells as input. Each cell was assigned a principal components (PC) score to
allow for multi-dimensional scaling of the data. Jackstraw and elbow functions were used to
determine the statistical significance of PC scores when different dimensionality parameters are
set. The output p-values were compared to deem 20 dimensions as an appropriate setting for
graph-based clustering of the cells. Cells were organized into a total of 17 clusters (0-16). Nonlinear dimensional reduction methods of t-SNE and uniform manifold and projection (UMAP)
were used to visualize the clustered cells.
Gene-Level Analysis
The most differentially expressed (up- and down-regulated) features of each cluster were
identified. The relative expression of cell type biomarkers from [26] across the 17 clusters were
compared to assign preliminary immune and neural cell identities in the tumor sample.
Analysis of Cells Enriched for ZFTA-RELA Oncogene Expression
The initial cell clustering revealed a distinct population of cells enriched for ZFTA-RELA
expression. These cells were re-clustered, and gene biomarkers for each subcluster were
determined using the same approaches as above. Top differentially expressed genes (> 1.00
log2NormalizedFoldChange) in each subcluster were inputted to Network Analyst [27] for Gene
Ontology Enrichment Analysis.

RESULTS
Transgenesis of ZFTA-RELA in a new mouse model of ST-EPN
Recently, in utero electroporation of a piggyBac system of plasmids has been shown to
be an effective method for inducing transgenesis of human genes in rodents[3,4]. We used the
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same approach to establish a novel mouse model of ST-EPN through the development of a
pPBCAG-ZFTA-RELA-HA donor plasmid (Fig. 1A) and in utero electroporation delivery of the
transgenes into neural progenitor cells in the lateral ventricles of embryonic mice at gestation age
12-14 (E12-14) (Fig. 1B). By postnatal day 21 (P21), these mice consistently developed tumors
expressing ZFTA-RELA-HA, as demonstrated through immunohistochemical staining (Fig. 1C).
Such tumors recapitulate the morphological (data not shown) and transcriptomic signatures of
ST-EPN tumors, which was confirmed via Gene Set Enrichment Analysis (GSEA)[20] comparing
expression of human ST-EPN, PF-EPN, and SP-EPN gene sets in mouse tumor and normal brain
tissue (Fig. 1D). This marks the first non-viral transgenic mouse model of ST-EPN.
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ZFTA-RELA-expressing cells are transcriptomically diverse from other cell types in the
ST-EPN tumor microenvironment
Given the highly heterogeneous nature of many malignant tumors, we derived a high
resolution transcriptomic profile of cells in the ST-EPN tumor microenvironment using scRNAseq (Fig. 2A). At age P35, a hydrocephalus mouse displaying significant symptoms of tumor
development was harvested for extraction of tumor tissue confined within clear boundaries from
adjacent normal tissue. Two separate single cell samples of the same tumor mass were sequenced
and processed following the 10X Genomics single cell dissolution and library preparation
protocol[5].
Sample one consisted of 20,087 cells with an average of 6389.4 read counts, 1930.4
aligned transcripts, and 20.5% percent of total features corresponding to mitochondrial genes per
cell. Sample two had 20,085 cells averaging 5814.1 reads, 1788.4 detected transcripts, and
21.0% percent mitochondrial features. T-distributed stochastic neighbor embedding (t-SNE)
clustering of cells from these separate runs revealed highly overlapping cell profiles in each
individual sample (Fig. 2B). Together, these metrics showed no significant batch effects were
evident between the two sequencing runs. Data from both runs was integrated for further
analysis.
Following integration, potential doublets and cells expressing high concentrations of
mitochondrial genes were filtered out (Fig. 2C), leaving a total of 23,217 cells. Principal
components analysis (PCA) and uniform manifold approximation and projection (UMAP)
multidimensional scaling were then used to cluster cells based on their gene expression patterns
(Fig. 3). Cells from the ST-EPN tumor microenvironment separated into 17 clusters (Fig. 3A),
each unique in their transcriptomic signatures (Fig. 3B). Distinctly, a cluster of 5,522 cells (i.e.
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cluster 0) deviated from the rest, and showed high expression of the ZFTA-RELA oncogene (Fig.
3C). Identification of published cell type biomarkers in the marker genes for the remaining
clusters revealed the presence of B and T lymphocytes, macrophages, microglia, endothelial, and
oligodendrocyte precursor cells (OPCs) in the tumor microenvironment. There was no significant
evidence of astrocytes or neurons that are ubiquitous in healthy CNS tissue, which suggests that
our sample contained minimal contamination of healthy brain tissue.
Top upregulated genes in ZFTA-RELA-positive cells are involved in major cancer-related
pathways
Given the hypothesis that ZFTA-RELA-expressing cells in cluster zero are major
contributors to ST-EPN tumor development, it would be expected that the upregulated marker
genes are key components of pathways and cellular processes linked to cancer malignancy.
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Indeed, many of the top biomarkers of ZFTA-RELA-positive cells were significantly associated
with signaling that promotes cell growth and proliferation, maintenance of undifferentiated cell
states, and ATP metabolism (Fig. 4).
The notch and p53 pathways play key roles in regulating cell proliferation,
differentiation, and apoptosis. Their dysregulation often leads to defects in highly controlled
cellular processes, enhancing the proliferative capacity and avoidance of cell death in oncogenic
cells[2,23]. Defective notch signaling also favors the maintenance of stemness in undifferentiated
cell populations, which contributes to tumor malignancy and chemoresistance[2,23]. Among the
top upregulated markers of fusion-expressing cells, Mdk, Dlk1, Peg3, and Meg3 encode notable
players in these signaling pathways (Fig. 4A, B), and are thought to promote ZFTA-RELAinitiated tumor development, though their specific role in tumor cell transformation and/or
development remains to be seen. Peg3 and meg3 transcripts were also detected at above-average
levels in cluster 15 and 16 cells, perhaps in compensatory response to ST-EPN tumorigenesis
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(Fig. 4B). In conjunction with the notch and p53 pathways, overactive receptor tyrosine kinase
(RTK) signal transduction enhances tumor cell proliferation. Importantly, Sparc, Htra1, and
Spp1 encode protein constituents of RTK downstream pathways, and were found to be
significantly upregulated in oncogenic cells (Fig. 4C), implying a role for RTK-associated gainof-function mutations in ST-EPN tumor growth.
The hyperactive nature of cancer cells places an elevated demand for ATP as an energy
source and expression of genes involved in its metabolism[8]. The expression of genes Ckb and
Tnnt3 was detected across all cell populations, but significantly elevated in cluster zero cells
(Fig. 4D). These trends suggest that cluster zero harbors oncogenic ZFTA-RELA-positive STEPN cells, and offer candidates for loss-of-function analysis in determining the necessary
components of tumorigenesis.
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ZFTA-RELA-expressing cells segregate into distinct subclusters representing unique cell
states
While the ZFTA-RELA-expressing cells of cluster zero share transcriptomic profiles
distinct from other cells in the tumor microenvironment, there may exist subpopulations that
were involved in different oncogenic processes at the time of sampling. Further sub-clustering of
cells overexpressing ZFTA-RELA was done to assess whether they associate with cellular states
that differentially contribute to ST-EPN tumor development. Isolated multidimensional scaling
of cluster zero cells segregated them into seven subclusters marked by different gene expression
patterns (Fig. 5A, B). The close proximity of these clusters in the UMAP plot suggests
similarities in their activity, perhaps a consequence of ubiquitous ZFTA-RELA expression in
these cells (Fig. 5C).
Gene Ontology Enrichment Analysis of top differentially expressed genes in these
subclusters identified unique cellular states. Subcluster four was demarcated by distinct markers
for mitotic cell division (Top2a, Mki67, Stmn1, Cdk1, Ube2c), while subcluster two expressed
many overall positive regulators of cell proliferation (Fdx1, Hmox1, Lif, Hbegf, Errfi1).
Subclusters three and six had genetic markers for vasculature development (Mgp, Ptn, Lum, Id3,
Cyr61) as well as angiogenesis and cell migration (Ctla2a, Cd93, Ly6c1, Tmem252, Egfl7),
respectively. Combined with the extracellular organizing activity (Cytl1, Nppc, Tnnt3, Rlbp1,
1700124L16Rik) of subcluster one, these cells may be sculpting a microenvironment with high
access to cell resources and metastatic potential. Interestingly, subclusters zero and five were
enriched for genes involved in immune response (Il1b, Cd14, Basp1, H2-Aa, Csf2rb) and cell
defense (Hbb-bs, C1qa, Tmsb4x, Mcpt2, C1qb). Such cells may have targeted the tumorigenic
cells to deter further growth.
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DISCUSSION
In this study, we created a novel mouse model of ST-EPN using a non-viral system of
piggyBac plasmids to introduce the oncogenic fusion ZFTA-RELA into neural progenitor cells of
the developing forebrain. Tumor cells from our model underwent scRNA-seq, which revealed
that significant expression ZFTA-RELA was found in less than a quarter of all sampled cells. The
other cells displayed biomarker signatures matching those of different types of immune cells (i.e.
B/T lymphocytes, macrophages) and CNS entities (i.e. microglia, OPCs, endothelial cells),
though matching these identities to the non-oncogene-expressing clusters remains an ongoing
effort. The lack of a robust cell typing program within Seurat and other analysis pipelines make
it difficult to distinguish between cell subtypes that exhibit similar gene expression patterns. For
example, a detailed scRNA-seq dataset from [24] list many overlapping biomarkers for germinal

center and memory B lymphocytes, which causes issues when redundant markers are
significantly upregulated across cell clusters or when a single cluster groups multiple cell types

He 15

together. Future efforts will be made to develop a consistent algorithm by which a combination
of genetic markers can be simultaneously probed across cell populations.
A question for which an answer remains elusive is which radial glial cell type serves as
the stem cell of origin of ST-EPN. Radial glial cells can differentiate to astrocytes,
oligodendrocytes, and neurons, and these precursor cells are marked by expression of GFAP,
MBP, and DCX, respectively[2]. In a prior experiment in the lab, expression of the ZFTA-RELA
oncogene was driven in specific neural progenitor cell populations by altering the upstream
promoter. The ubiquitous synthetic CAG promoter produced the most aggressive tumors, the
MBP and GFAP promoters resulted in less aggressive tumors, and the DCX promoter induced no
tumors. Consequently, we expected oncogenic cells to concurrently express these markers.
Instead, MBP and GFAP were found in the marker gene sets of cluster 14 and 6, but not
significantly expressed in cluster 0. It may be possible that chromatin remodeling by ZFTARELA disrupts normal lineage specification programs that indefinitely prolongs the radial glial
cell state.
When examining the role of upregulated marker genes in the oncogenic cell population,
we found many of them belong to key cancer-related pathways. In an analysis done by the Cheng
Lab (JAX-GM), a ZFTA-binding motif [9] was significantly enriched in promoter and enhancer
regions of 209 of the cluster zero marker genes compared to the rest of the genome. Seven out of
nine of the previously discussed genes (meg3, peg3, dlk1, mdk, htra1, spp1, ckb) were included
on this list, implying that elevated activity of ZFTA when expressed in the ZFTA-RELA fusion
may be driving increased expression of these genes and their downstream signaling. If this were
true, however, its effect on tumorigenesis remains unclear. While enhancing Notch and RTK
signaling, as well as ATP metabolism would be expected to accelerate tumor progression,
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upregulation of the p53 pathway seems counterproductive. Putative tumor suppressor p53 is not
typically affected by a gain-of-function mutation in ST-EPN tumors, so increasing its activity
would likely deter oncogenesis. Further study of these marker genes via CRISPR-Cas9 mediated
loss of function analysis in vivo through our mouse model and in vitro through cell culture will
help elucidate their role in ST-EPN tumorigenesis.
Many parallel processes contribute to tumor growth, so whether the oncogenic cells in
cluster zero represent different cellular sub-states was investigated by sub-clustering just the
5522 cells. We found that applying the same clustering approach as we did with the whole
dataset yielded seven subclusters that were defined by varying gene ontology biological process
terms. Embedded in this population are cells that are actively cycling and restructuring the
extracellular environment and surrounding vasculature. These may be responsible for tumor
growth and metastasis, and exclusively targeting them may be of clinical utility for disease
management. Certainly, preliminary experiments are necessary for clarifying their specific
functions before the efficacy of such an approach can be determined.
Interestingly, subclusters 0 and 5 expressed marker genes involved in immune
response and cell defense. Invading immune cells that attach or engulf tumorigenic cells may
contribute to some of these transcriptional patterns. Whether the cells respond to immune
defense is unclear, but the potential for this immunologically “hot” cell population to show
clinical response to immunotherapies such as immune checkpoint inhibitors warrants further
investigation[23]. Severe T cell exhaustion through inherent immune checkpoints PD-1/PDL-1,
CTLA-4, and HAVCR4 is prevalent in other solid tumors, including pediatric glioblastomas
(GBM)[23]. Both GBM and ST-EPN arise in the brain and may originate from similar stem cell
lineages. Consequently, immunotherapies should be explored as treatment options for both tumor
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types, as these commonalities may point to similar clinical outcomes.
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